Apoptosis and p53 suppressor gene protein expression in human anterior pituitary adenomas

1997 ◽  
Vol 136 (4) ◽  
pp. 382-387 ◽  
Author(s):  
Victoria L Green ◽  
Michael C White ◽  
Leslie J Hipkin ◽  
Richard V Jeffreys ◽  
Patrick M Foy ◽  
...  
Keyword(s):  
Protein Expression ◽  
Pituitary Adenomas ◽  
Anterior Pituitary ◽  
P53 Protein ◽  
Tumour Size ◽  
Suppressor Gene ◽  
Tumour Suppressor ◽  
Tumour Type ◽  
P53 Protein Expression ◽  
Human Anterior Pituitary

Abstract Human anterior pituitary adenomas proliferate and express the p53 tumour suppressor gene protein, but it is not known if apoptosis (programmed cell death) occurs. Therefore, the detection of apoptosis was undertaken in tumorous human anterior pituitary tissue and compared with p53 protein expression, tumour type and tumour size. Apoptosis (detected by the in situ end labelling technique) and p53 suppressor gene protein (detected by DO. 1-antibody immunocytochemistry) were determined in formalin-fixed and paraffin-embedded tissue from 37 human pituitary adenomas (2 macroprolactinomas, 9 somatotrophinomas and 26 non-functioning adenomas). Two normal anterior pituitaries were also included in this study. Pre-operative tumour size was scored 1 to 4 from magnetic resonance imaging radiology. Apoptosis was found in 7 of 29 tumours (24%), 11% of somatotrophinomas and 33% of non-functioning adenomas, although this difference was not significant. The p53 tumour suppressor protein was found in 7 of 31 tumours (23%), 33% of somatotrophinomas and 19% of nonfunctioning adenomas. Apoptosis and p53 protein expression were not found in normal anterior pituitary. In conclusion, apoptosis occurs in human anterior pituitary adenomas, but no significant association was found between apoptosis and p53 protein expression, tumour type or tumour size. European Journal of Endocrinology 136 382–387

scholarly journals Correlation of cell cycle regulatory proteins (p53 and p16ink4a) and bcl-2 oncoprotein with mitotic index and thickness of primary cutaneous malignant melanoma

2010 ◽  
Vol 10 (4) ◽  
pp. 276-281 ◽  
Author(s):  
Miloš Kostov ◽  
Žaklina Mijović ◽  
Dragan Mihailović ◽  
Snežana Cerović ◽  
Miroslav Stojanović ◽  
...  
Keyword(s):  
Protein Expression ◽  
Mitotic Index ◽  
P53 Protein ◽  
Suppressor Gene ◽  
Tumor Thickness ◽  
Loss Of Function ◽  
Primary Cutaneous Malignant Melanoma ◽  
P53 Protein Expression ◽  
Malignant Skin ◽  
Cell Cycle Regulatory Proteins

The purpose of the study was to determine the frequency of expression p53 and p16INK4a proteins and bcl2- oncoprotein in malignant skin melanoma and to determine their correlation with the proliferative index and tumor thickness. The study involved 53 patients: 27 (51%) male and 26 (49%) female. Mitotic index showed a correlation with p53 protein expression, a negative correlation with p16INK4a protein expression. Statistically significant correlations were determined between the Breslow tumor thickness, Clark invasion level and p53 protein expression, as well as Breslow tumor thickness and bcl-2 oncoprotein expression (p<0.05), whereas there was no correlation between the p16INK4a protein expression and melanoma thicknes and Clark invasion level. Overexpression p53 protein and bcl-2 oncoprotein, with the loss p16INK4a protein of expression in the nodular melanoma, confirms a frequent loss of function of these tumor suppressor gene and oncogene, and indicates a vertical tumor growth phase. The loss of tumor suppression function the p53 protein and bcl-2 oncoprotein overexpression in cutaneous melanoma correlates with larger tumor thickness, whereas the overexpression of mutated p53 protein and loss p16INK4a protein of expression indicate a higher proliferative tumour potential. Therefore, these evaluated proteins may be the aggressive biological tumour activity markers.

Analysis of p53 Protein Expression in Hepatocellular Carcinoma

2016 ◽  
Vol 25 (3) ◽  
pp. 345-349 ◽  
Author(s):  
Florin Graur ◽  
Luminita Furcea ◽  
Emil Mois ◽  
Andrei Biliuta ◽  
Aliz-Timea Rozs ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Hepatitis B ◽  
Protein Expression ◽  
P53 Protein ◽  
Tumour Size ◽  
Study Group ◽  
Chi Square ◽  
Altered Expression ◽  
P53 Protein Expression

Background & Aims: Hepatocellular carcinoma (HCC) has a growing incidence and studies regarding the risk factors or pathogenesis for this type of carcinoma benefit special interest. This study evaluates the correlations between p53 protein expression and clinical and laboratory factors in patients withHCC. Methods: The study group included 76 patients diagnosed with HCC, either by biopsy or after surgical resection (with curative intent). Immunohistochemistry for p53 protein assessment was performed in all patients. Correlations between the protein 53 expression and age, tumour size, viral infection, liver cirrhosis were performed using the chi-square test (Pearson‘s chi-square) together with the contingency coefficient Kendall‘s coefficient in the tau-b form. Results: In the study group, 51 patients were male (67%) and 25 female (33%). Cirrhosis due to hepatitis virus B or C infection (in a proportion of 63% of the study group) was not significantly associated with the presence of HCC. Altered expression of p53 protein was observed in 69 patients (91%). The relationship between p53 protein expression and patient sex (p=0.067), age (p=0.531), tumour size (p=0.270), presence of hepatitis B and C viral infections (p=0.7), and of liver cirrhosis (p=0.511) was not statistically significant. Conclusion: The p53 protein expression was not significantly associated with the demographic characteristics of the patients, tumour size, presence of viral B and C infections or liver cirrhosis. Abbreviations: HBV: hepatitis B virus; HCV: hepatitis C virus; HCC: hepatocellular carcinoma; TP53: tumour protein p53; MDR: multi-drug resistance gene.

scholarly journals 54 Prognostic value of p53 protein expression in breast cancer

2020 ◽  
Author(s):  
S Ben Slama ◽  
D Bacha ◽  
A Ben Amor ◽  
A Halouani ◽  
A Lahmar
Keyword(s):  
Breast Cancer ◽  
Protein Expression ◽  
Prognostic Value ◽  
P53 Protein ◽  
P53 Protein Expression

Dispersed Human Anterior Pituitary Adenomas Preferentially Attach to Poly-L-Lysine Coated Wells

1991 ◽  
Vol 81 (s25) ◽  
pp. 29P-30P
Author(s):  
SL Atkin ◽  
AM Landolt ◽  
RV Jeffreys ◽  
White MC
Keyword(s):  
Pituitary Adenomas ◽  
Anterior Pituitary ◽  
Human Anterior Pituitary

p53 protein expression in sequential biopsies of oral dysplasias and in situ carcinomas

1995 ◽  
Vol 24 (1) ◽  
pp. 18-22 ◽  
Author(s):  
J. A. Regezi ◽  
R. J. Zarbo ◽  
E. Regev ◽  
S. Pisanty ◽  
S. Silverman ◽  
...  
Keyword(s):  
Protein Expression ◽  
P53 Protein ◽  
P53 Protein Expression

scholarly journals Thyrotrophin receptor protein expression in normal and adenomatous human pituitary

2000 ◽  
Vol 167 (1) ◽  
pp. 7-13 ◽  
Author(s):  
M Theodoropoulou ◽  
T Arzberger ◽  
Y Gruebler ◽  
Z Korali ◽  
P Mortini ◽  
...  
Keyword(s):  
Protein Expression ◽  
Pituitary Adenomas ◽  
Anterior Pituitary ◽  
Preliminary Evidence ◽  
Positive Control ◽  
Negative Control ◽  
Receptor Protein ◽  
Human Pituitary ◽  
Thyrotrophin Releasing Hormone ◽  
Regulatory Pathways

Thyrotrophin (TSH) synthesis and secretion is under the positive control of thyrotrophin releasing hormone and under the negative control of the thyroid hormones. However, it is hypothesised that TSH has a direct effect on the regulation of its own synthesis through an intrapituitary loop mediated by pituitary TSH receptors (TSH-R). The aim of this investigation was to study the expression of TSH-R in normal human pituitary at mRNA and protein levels, and to compare the pattern of protein expression between different pituitary adenomas. Using RT-PCR we were able to detect TSH-R mRNA in the normal pituitary, and immunohistochemical studies showed TSH-R protein expression in distinct areas of the anterior pituitary. Double immunostaining with antibodies against each of the intrapituitary hormones and S100 revealed that TSH-R protein is present in thyrotrophs and folliculostellate cells. Examination of 58 pituitary adenomas, including two clinically active and two clinically inactive thyrotroph adenomas, revealed TSH-R immunopositivity in only the two clinically inactive thyrotroph adenomas. This study shows, for the first time, the presence of TSH-R protein in the normal anterior pituitary and in a subset of thyrotroph adenomas. The expression of TSH-R in the thyrotroph and folliculostellate cell subpopulations provides preliminary evidence of a role for TSH in autocrine and paracrine regulatory pathways within the anterior pituitary gland.

Sign in / Sign up

Export Citation Format

Share Document